

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Jul 2025

Underlined items indicate changes from the previous announcement in Apr 2025.

Strategic Brands (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III	In-house [Co-development with Pfizer]	
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-II		
			Acute myeloid leukemia in pediatric patients	P-III		
zolbetuximab IMAB362 (VYLOY)	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma (combo with pembrolizumab and chemotherapy)	P-III	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
fezolinetant ESN364 (VEOZAH***)	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	China P-III Japan P-III	In-house (Ogeda)	
			Vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy	P-III		

Strategic Brands (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
avacincaptad pegol (IZERVAY)	Pegylated RNA aptamer	Complement C5 inhibitor	Geographic atrophy secondary to age-related macular degeneration	Japan Filed (Feb 2025)	In-house (Iveric Bio)	
			Stargardt disease	P-II		

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** Approved as "VEOZA" in ex-US.

Updates from the previous announcement (Apr 2025):
enfortumab vedotin: Discontinued Phase 1 program for non-muscle-invasive bladder cancer. Discontinued Phase 2 program for other solid tumors.

Programs with Focus Area approach

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
Immuno-oncology	ASP1570	Small molecule	DGKζ inhibitor	Cancer	P-I	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]	
	ASP1002	Antibody	Anti-Claudin 4 and anti-CD137 bispecific antibody	Cancer	P-I	In-house	
Targeted Protein Degradation	ASP3082	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
	ASP4396	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
Genetic regulation	resamirigene bilparvovec AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	zocaglusagene nuzaparvovec AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-II	In-house (Audentes Therapeutics)	
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelial cells	Geographic atrophy secondary to age-related macular degeneration	P-I	In-house (Ocata Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Apr 2025):
ASP1012: Discontinued Phase 1 program for cancer.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
mirabegron YM178	Small molecule	β ₃ receptor agonist	Neurogenic detrusor overactivity in pediatric patients (aged 6 months to less than 3 years)	Europe P-III	In-house	
roxadustat ASP1517/FG-4592	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
abiraterone decanoate ASP5541/PRL-02	Small molecule	CYP17 lyase inhibitor	Prostate cancer	P-I	In-house (Propella Therapeutics)	
ASP546C/XNW27011	Antibody-drug conjugate (ADC)	Claudin 18.2-targeted ADC	Cancer	P-I	Evopoint Biosciences	Astellas has worldwide rights excluding China's mainland, Hong Kong, Macau, and Taiwan.
ASP5502	Small molecule	STING inhibitor	Primary Sjogren's syndrome	P-I	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Apr 2025):

ASP546C/XNW27011: Added a program.

Rx+ Program

As of Jul 2025

Category	Program	Concept	Status*	Partner	Remarks
Digital health	BlueStar	Digital therapeutic for the management of diabetes	Pivotal study (Japan)	Welldoc Roche Diabetes Care Japan	
Drug-device combination	pudexacianinium chloride ASP5354	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	Stryker	
Implantable medical device	Implantable bladder device	Implantable device for underactive bladder	FDA approved to enter into early feasibility study	(iota Biosciences)	

* The list shows the most advanced stage if the stages are different depending on the region.